CN104487073A - 改善肝功能的方法 - Google Patents

改善肝功能的方法 Download PDF

Info

Publication number
CN104487073A
CN104487073A CN201380033568.7A CN201380033568A CN104487073A CN 104487073 A CN104487073 A CN 104487073A CN 201380033568 A CN201380033568 A CN 201380033568A CN 104487073 A CN104487073 A CN 104487073A
Authority
CN
China
Prior art keywords
methazolamide
patient
treatment
liver
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380033568.7A
Other languages
English (en)
Chinese (zh)
Inventor
肯·瓦尔德
盖伊·克里普纳
杰夫·尼克尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nayar Metabolism Co Ltd
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Priority to CN201811294792.2A priority Critical patent/CN109498623A/zh
Publication of CN104487073A publication Critical patent/CN104487073A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201380033568.7A 2012-05-24 2013-03-15 改善肝功能的方法 Pending CN104487073A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811294792.2A CN109498623A (zh) 2012-05-24 2013-03-15 改善肝功能的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US61/651,335 2012-05-24
US201261666574P 2012-06-29 2012-06-29
US61/666,574 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811294792.2A Division CN109498623A (zh) 2012-05-24 2013-03-15 改善肝功能的方法

Publications (1)

Publication Number Publication Date
CN104487073A true CN104487073A (zh) 2015-04-01

Family

ID=49622927

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380033568.7A Pending CN104487073A (zh) 2012-05-24 2013-03-15 改善肝功能的方法
CN201811294792.2A Pending CN109498623A (zh) 2012-05-24 2013-03-15 改善肝功能的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811294792.2A Pending CN109498623A (zh) 2012-05-24 2013-03-15 改善肝功能的方法

Country Status (15)

Country Link
US (2) US20150150855A1 (enExample)
EP (1) EP2854807A4 (enExample)
JP (2) JP6360826B2 (enExample)
KR (1) KR20150023405A (enExample)
CN (2) CN104487073A (enExample)
BR (1) BR112014029308A2 (enExample)
CA (1) CA2874513A1 (enExample)
CO (1) CO7160082A2 (enExample)
HK (1) HK1209051A1 (enExample)
MX (1) MX362111B (enExample)
NZ (2) NZ702645A (enExample)
RU (1) RU2653478C2 (enExample)
SG (2) SG11201407787VA (enExample)
WO (1) WO2013173859A1 (enExample)
ZA (1) ZA201408704B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2106260T3 (pl) 2007-01-25 2018-06-29 NAIA Metabolic, Inc. Środki uwrażliwiające na insulinę i sposoby leczenia
HK1209041A1 (en) * 2012-05-24 2016-03-24 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801375A (zh) * 2007-01-25 2010-08-11 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (en) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Substituted indole-o-glucosides
HK1209041A1 (en) * 2012-05-24 2016-03-24 Verva Pharmaceuticals Ltd A method of weight reduction

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801375A (zh) * 2007-01-25 2010-08-11 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OH, HYO JEONG等: "Association of serum alanine aminotransferase and γ-glutamyltransferase levels within the reference range with metabolic syndrome and nonalcoholic fatty liver disease", 《THE KOREAN JOURNAL OF HEPATOLOGY》 *

Also Published As

Publication number Publication date
MX362111B (es) 2019-01-07
CO7160082A2 (es) 2015-01-15
KR20150023405A (ko) 2015-03-05
RU2014152196A (ru) 2016-07-20
HK1209051A1 (en) 2016-03-24
JP6360826B2 (ja) 2018-07-18
WO2013173859A1 (en) 2013-11-28
NZ702645A (en) 2016-08-26
US20150150855A1 (en) 2015-06-04
RU2653478C2 (ru) 2018-05-08
MX2014014317A (es) 2015-08-10
SG10201705388XA (en) 2017-07-28
BR112014029308A2 (pt) 2017-06-27
SG11201407787VA (en) 2014-12-30
JP6412241B2 (ja) 2018-10-24
ZA201408704B (en) 2018-07-25
CA2874513A1 (en) 2013-11-28
NZ723206A (en) 2018-02-23
JP2018090589A (ja) 2018-06-14
CN109498623A (zh) 2019-03-22
US20180333399A1 (en) 2018-11-22
EP2854807A4 (en) 2016-03-16
JP2015517534A (ja) 2015-06-22
EP2854807A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
JP6442284B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
AU2025201814A1 (en) Therapeutic uses of GLP1R agonists
TW201406374A (zh) 用於治療代謝性疾病之醫藥組合
JP2014527506A (ja) 糖尿病治療のための組み合わせ
JP6412241B2 (ja) 肝機能改善法
US20210169858A1 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN104582701B (zh) 减轻体重的方法
AU2016206292B2 (en) A method of improving liver function
Mousa et al. Literature review of oral treatment of type 2 diabetes mellitus
TW201731506A (zh) 糖尿病治療劑之倂用
CN106061940A (zh) 治疗糖尿病和由其引发的并发疾病的化合物
Chon et al. Diabetic Pharmacotherapies in Kidney Disease
CN114794487A (zh) 一种治疗糖尿病的方法
Gallwitz Sitagliptin and Metformin in Fixed Dose Combination: The Emerging Evidence of its Therapeutic Impact in Type 2 Diabetes
MX2012014757A (es) Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180508

Address after: Grand Cayman, Cayman Islands

Applicant after: Nayar metabolism Co., Ltd.

Address before: Vitoria Australia

Applicant before: VERVA PHARMACEUTICALS LTD

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150401